Form 4 for VNRX VOLITIONRX LTD
Accepted 2024-09-04 00:00:00 ET · period of report 2024-09-01 · accession 0001477932-24-005497 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-04 | 2024-09-01 | VNRX | Butera Salvatore Thomas | CEO - Volition Veterinary | A - Grant | $0.00 | +35.8K | 287.8K | +14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-01 | A | A | 35,783 | $0.00 | 287,783 | D | — | — | (F1) On September 1, 2024, the reporting person was awarded 35,783 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 11,928 units, 11,928 units, and 11,927 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. |